We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Centessa Pharmaceuticals PLC | NASDAQ:CNTA | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.36 | -3.16% | 11.04 | 11.08 | 11.67 | 11.61 | 10.95 | 11.42 | 332,516 | 01:00:00 |
FORM 8-K |
England and Wales | 001-04321 | 98-1612294 | ||||||||||||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Ordinary shares, nominal value £0.002 per share | CNTA | Nasdaq Stock Market, LLC* | ||||||||||||
American Depositary Shares, each representing one ordinary share, nominal value £0.002 per share | CNTA | Nasdaq Stock Market, LLC |
Ordinary Resolutions | For | Against | Withheld | Broker Non-Votes | ||||||||||
To re-appoint as a director Carol Stuckley, M.B.A., who retires by rotation in accordance with the Company’s articles of association. | 73,869,967 | 243,946 | 80,631 | — | ||||||||||
To re-appoint as a director Brett Zbar, M.D., who retires by rotation in accordance with the Company’s articles of association. | 73,820,796 | 293,108 | 80,640 | — | ||||||||||
To re-appoint as a director Mathias Hukkelhoven, Ph.D., who retires by rotation in accordance with the Company's articles of association. | 73,845,513 | 268,291 | 80,740 | — | ||||||||||
To re-appoint KPMG LLP, a United Kingdom entity, as UK statutory auditors of the Company, to hold office until the conclusion of the next meeting at which the Company’s annual accounts and reports are laid before the Company. | 74,152,822 | 10,473 | 31,249 | — | ||||||||||
To ratify the re-appointment of KPMG LLP, a Delaware limited liability partnership, as the Company’s independent registered public accounting firm, for the financial year ending December 31, 2023. | 74,161,945 | 1,450 | 31,149 | — | ||||||||||
To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the financial year ending December 31, 2023. | 74,160,344 | 1,954 | 32,246 | — | ||||||||||
To receive and adopt our U.K. statutory annual accounts and reports for the financial year ended December 31, 2022 and to note that the Company’s directors do not recommend the payment of any dividend for the financial year ended December 31, 2022. | 74,160,295 | 2,220 | 32,029 | — | ||||||||||
To receive and approve, on an advisory basis, the Company’s U.K. statutory directors’ remuneration report for the financial year ended December 31, 2022. | 73,897,670 | 264,635 | 32,239 | — |
By: | /s/ Saurabh Saha | |||||||
Name: | Saurabh Saha, M.D., Ph.D. | |||||||
Title: | Chief Executive Officer |
1 Year Centessa Pharmaceuticals Chart |
1 Month Centessa Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions